Literature DB >> 29528202

Early predictors of unresponsiveness to high-flow nasal cannula therapy in a pediatric emergency department.

Anıl Er1, Aykut Çağlar1, Fatma Akgül1, Emel Ulusoy1, Hale Çitlenbik1, Durgül Yılmaz1, Murat Duman1.   

Abstract

AIM: High-flow nasal cannula (HFNC) is a new treatment option for pediatric respiratory distress and we aimed to assess early predictive factors of unresponsiveness to HFNC therapy in a pediatric emergency department (ED).
METHOD: Patients who presented with respiratory distress and were treated by HFNC, were included. The age, gender, weight, medical history, diagnosis, vital signs, oxygen saturation/fraction of inspired oxygen (SpO2 /FiO2 ) ratio, modified Respiratory Distress Assessment Instrument (mRDAI) scores, medical interventions, duration of HFNC therapy, time to escalation, adverse effects, and laboratory test results were obtained from medical and nursing records. The requirement of a higher level of respiratory support due to unchanged or increased RR compared to initial RR, incipient, or progressive respiratory acidosis, incipient hemodynamic instability was defined as unresponsiveness to HFNC.
RESULTS: The study enrolled 154 children with a median age of 10 months (interquartile range [IQR], 5.7-22.5 months). The diagnosis was acute bronchiolitis in 59 patients (38.3%), bacterial pneumonia in 64 patients (41.6%), and atypical or viral pneumonia in 31 patients (20.1%). Twenty-five patients (16.2%) were in the unresponsive group, and the median time for escalating respiratory support was 7 h (IQR: 4-20 h). The unresponsive group had lower SpO2 and SpO2 /FiO2 (SF) ratio on admission, lower venous pH, and higher partial pressure of carbon dioxide (pCO2 ) (P = 0.002, P = 0.012, and P = 0.001, respectively). Also the alteration of RR, mRDAI score, and SF ratio at the first hour was greater in the responsive group. The cut-off value of SF ratio at the first hour of HFNC was 195 for unresponsiveness.
CONCLUSION: The low initial SpO2 and SF ratio, respiratory acidosis, and SF ratio less than 195 at the first hours of treatment were related to unresponsiveness to HFNC therapy in our pediatric emergency department.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  SpO2/FiO2 (S/F) ratio; emergency department; high-flow nasal cannula; pediatrics; respiratory distress

Mesh:

Year:  2018        PMID: 29528202     DOI: 10.1002/ppul.23981

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  5 in total

1.  Frequency and Correlates of Pediatric High-Flow Nasal Cannula Use for Bronchiolitis, Asthma, and Pneumonia.

Authors:  Colin M Rogerson; Aaron E Carroll; Wanzhu Tu; Tian He; Titus K Schleyer; Courtney M Rowan; Arthur H Owora; Eneida A Mendonca
Journal:  Respir Care       Date:  2022-05-24       Impact factor: 2.339

2.  Predicting High Flow Nasal Cannula Failure in an Intensive Care Unit Using a Recurrent Neural Network With Transfer Learning and Input Data Perseveration: Retrospective Analysis.

Authors:  George Pappy; Melissa Aczon; David Ledbetter; Randall Wetzel
Journal:  JMIR Med Inform       Date:  2022-03-03

3.  Factors associated with treatment failure of high-flow nasal cannula among children with bronchiolitis: a single-centre retrospective study.

Authors:  Michelle D'Alessandro; Thuva Vanniyasingam; Ashaka Patel; Ronish Gupta; Lucy Giglia; Giuliana Federici; Gita Wahi
Journal:  Paediatr Child Health       Date:  2020-08-02       Impact factor: 2.253

4.  SpO2/FiO2 as a predictor of high flow nasal cannula outcomes in children with acute hypoxemic respiratory failure.

Authors:  Ga Eun Kim; Sun Ha Choi; Mireu Park; Jae Hwa Jung; Myeongjee Lee; Soo Yeon Kim; Min Jung Kim; Yoon Hee Kim; Kyung Won Kim; Myung Hyun Sohn
Journal:  Sci Rep       Date:  2021-06-29       Impact factor: 4.379

5.  Nasogastric tube, a warning sign for high-flow nasal cannula failure in infants with bronchiolitis.

Authors:  Milena Siciliano Nascimento; Danielle E R Quinto; Gisele C Z Oliveira; Celso M Rebello; Cristiane do Prado
Journal:  Sci Rep       Date:  2020-09-28       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.